Chromosome 7 polysomy and biomarker combinations as potential predictors of gefitinib efficacy in non-small cell lung cancer (NSCLC).
John S. Coon(Rush University Medical Center), Philip Bonomi(Rush University Medical Center), Susan Jewell(Netherlands Institute for Radio Astronomy), Victoria Villaflor(University of California, Irvine Medical Center), Lela Buckingham(Rush University Medical Center), Ann M. Mauer(University of Chicago), Kris Jacobson, M. Gale(Rush University), Larry E. Morrison(Abbott Fund), Tariq Muzzafar(The University of Texas MD Anderson Cancer Center)
Clinical Cancer Research
October 1, 2006
Cited by 0
Related Papers
Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
|Journal of Clinical Oncology|2004|1.1k
Fluorescence In Situ Hybridization (FISH) as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma
|The American Journal of Surgical Pathology|2009|470
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial
|The Lancet Oncology|2014|263
A Highly Specific and Discriminatory FISH Assay for Distinguishing Between Benign and Malignant Melanocytic Neoplasms
|The American Journal of Surgical Pathology|2012|227
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma
|Annals of Oncology|2013|125